Skip to main content
Fig. 9 | Breast Cancer Research

Fig. 9

From: CGRRF1, a growth suppressor, regulates EGFR ubiquitination in breast cancer

Fig. 9

Breast cancer patients with lower CGRRF1 have poor overall survival. a Kaplan-Meier analysis of breast cancer according to CGRRF1 expression levels. The CGRRF1 expression levels and clinical outcomes of a published dataset [13] were extracted from Oncomine. Patients were ranked according to the CGRRF1 expression levels in their breast tumors. We then divided the patients into four groups (CGRRF1 levels: high > intermediate 2 > intermediate 1 > low). The numbers (n) of patients in each group are indicated. n was assigned so that each group had almost an equal number of patients. Kaplan-Meier curves were then derived from each group. The Wilcoxon test was used to evaluate significance. b Estrogen receptor-positive breast cancer patients in the van de Vijver dataset [13] were analyzed. Patients were ranked according to CGRRF1 mRNA levels and divided into two groups according to the indicated methods for the Kaplan-Meier curve analysis: (1) equally divided; (2) low CGRRF1 expression (bottom 1/4 of the total cohort) vs. the remaining 3/4 of the cohort; (3) low CGRRF1 expression (bottom 1/5 of the total cohort) vs. the remaining 4/5 of the cohort; (4) low CGRRF1 expression (bottom 1/6 of the total cohort) vs. the remaining 5/6 of the cohort. The Wilcoxon test was used to evaluate significance. P values for the tests between the groups are indicated. c CGRRF1 transcript levels in different subtypes of breast cancer (data extracted from UCSC Xena, TCGA breast cancer (BRCA)). The asterisk (*) means p < 0.001 as compared to other subtypes. d Kaplan-Meier curves in Luminal A breast cancer patients from the METABRIC cohort. Patients were equally separated into two groups based on the expression of CGRRF1 in their breast cancers. P values from both the log-rank test and Wilcoxon test are shown

Back to article page